Discover
CVKD
Cadrenal Therapeutics, Inc.
3.17
1 x 3.04
1 x 2.98
bid
ask
-
0.17
5.09%
1 @ 04:00 PM
3.13 -0.04 (1.26%)
| Ytd | -53.24% | |
| 1y | -72.84% |
2.91
day range
3.78
2.55
52 week range
14.64
| Open | 3.22 | Prev Close | 3.34 | Low | 2.91 | High | 3.78 | Mkt Cap | 9.76M |
| Vol | 467.57K | Avg Vol | 70.05K | EPS | -5.59 | P/E | N/A | Forward P/E | -3.02 |
| Beta | N/A | Short Ratio | 1.17 | Inst. Own | 4.75% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-21 | 50-d Avg | 4.69 | 200-d Avg | 8.05 | 1yr Est | 35.67 |
CVKD News
globenewswire.com
Cadrenal Therapeutics Announces up to $8.8 Million Private Placement Priced At-The-Market Under Nasd
$3 million upfront with up to approximately $5.8 million of potential additional gross proceeds upon
benzinga.com
Cadrenal Therapeutics Says Late-Breaking Clinical Data On 12-Lipoxygenase Inhibitor, CAD-1005, Accep
Selection highlights the clinical value potential of Cadrenal’s first-in-class 12-lipoxygenase inhib
benzinga.com
Cadrenal Therapeutics Plans To Submit An FDA Rare Pediatric Disease Designation Request For Tecarfar
Company to present Phase 3-ready pipeline, 12-LOX platform, and pediatric rare-disease expansion to
benzinga.com
Cadrenal Therapeutics Plans To Initiate Phase 2a Proof-Of-Concept Clinical Trial Of CAD-1005, Being
New high-value indication for Phase 3-ready asset with data intended to support clinical development
benzinga.com
Cadrenal Therapeutics Announces Participation In BIO 2026; To Host Partnering Meetings To Discuss De
Lead asset CAD-1005 being researched for prevention of life-threatening blood clots in patients with